Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

C-Maf T-cell switch factor: Important component of Boston Life Science's R&D

July 19, 1996

Genome Therapeutics and Merck & Co. sign licensing agreement

July 19, 1996

Roche licenses PCR technology to Immuno

July 12, 1996

GenPharm describes high-affinity human IgG monoclonal antibodies

July 12, 1996

LCR Technology covered under U.S. patent

July 12, 1996

SmithKline Beecham/Human Genome Sciences human genome collaboration no longer exclusive

July 12, 1996

Oculex receives grants for ocular drug delivery research

July 12, 1996

Heliosynthese and Scotia receive EEC Eureka award for microalgae research

July 12, 1996

Phytera and Tsumura Juntendo collaborate in rheumatoid arthritis/allergy R&D

July 12, 1996

Collaboration on signal transduction inhibitor drug discovery announced

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 5, 2025.
CMS vows to put more emphasis on MA plans’ prior authorization
BioWorld MedTech
Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Associate degree: PTC’s hints of phase II HD efficacy studied
BioWorld
PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t...